CoLucid Pharmaceuticals was founded with a primary goal of developing lasmiditan for the acute treatment of migraine. The Company has three clinical trials underway—SAMURAI, SPARTAN, and GLADIATOR—which will result in more than 15,000 patient exposures with lasmiditan.
Lasmiditan is being developed in two formulations: an oral medication for the acute treatment of migraine in adults, and also as intravenous formulation for administration by health care professionals.
Find all CoLucid Committee Charters and Governance Documents.
Mar 28, 2012
Jun 7, 2016